


I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: April 30, 2009 Signature: 
(Heather R. Kissling)

Docket No.: 30694/41889
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
David Wallach et al.

Application No.: 10/573,138

Confirmation No.: 3144

Filed: November 6, 2006

Art Unit: 1644

For: Anti-NIK Antibodies and Uses Thereof

Examiner: WEN, Sharon X.

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

In response to the restriction requirement set forth in the Office Action mailed March 31, 2009, Applicants hereby provisionally elect the claims of Group I, i.e., claims 1-16 and 19-38, for continued examination. In response to the Office's requirement for election of species, Applicants elect SEQ ID NO: 7. Claims 1-4, 7-11, 14-16, 19-21, 24, 27, 30-32, and 35-38 read on the elected species. Applicants respectfully traverse the requirement for restriction for the reasons set forth below.

The Restriction Requirement

The Examiner has required restriction among the following groups of claims:

- I. Claims 1-16 and 19-38, drawn to an anti-NF-κB-inducing kinase (NIK) antibody, a hybridoma producing the antibody, a preparation comprising the antibody, and a pharmaceutical composition comprising the antibody.